score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline	Guideline		Copy Number	AR	Amplification				0.0	0.0		Putatively Actionable	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf	Putatively Actionable	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor activation is a potential mechanism of recurrence of prostate cancer during androgen deprivation therapy.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf						0				AR Amplification		PROS12319B-SU2C-06115118	PROS12319B-SU2C-06115118-Tumor-SM-4W2ND	
Putatively Actionable	Preclinical			Copy Number	CCNE1	Amplification				0.0	0.0		Putatively Actionable	Bortezomib	Proteasome inhibition	Targeted therapy	Sensitivity to Bortezomib was observed in ovarian cancer cell lines.	"Etemadmoghadam, Dariush, et al. ""Synthetic lethality between CCNE1 amplification and loss of BRCA1."" Proceedings of the National Academy of Sciences 110.48 (2013): 19489-19494."	https://doi.org/10.1073/pnas.1314302110													0				CCNE1 Amplification	1.0	PROS12319B-SU2C-06115118	PROS12319B-SU2C-06115118-Tumor-SM-4W2ND	
Investigate Actionability	Preclinical			Rearrangement	SLC45A3	Fusion	SLC45A3--ETV1			0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Rearrangements in BRAF are rare but may result in dependencies that can be targeted with RAF and MAP2K1 inhibitors.	Palanisamy N, Ateeq B, Kalyana-sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010;16(7):793-8.	https://doi.org/10.1038/nm.2166													0				SLC45A3--ETV1 Fusion	1.0	PROS12319B-SU2C-06115118		
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G266R	0.4923	65.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0.0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	22.0	0.5909	0.9979	TP53 p.G266R (Missense)		PROS12319B-SU2C-06115118	PROS12319B-SU2C-06115118-Tumor-SM-4W2ND	PROS12319B-SU2C-06115118-Normal-SM-4W2NW
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						PROS12319B-SU2C-06115118		
Biologically Relevant				Copy Number	BRIP1	Amplification				0.0	0.0																					0				BRIP1 Amplification		PROS12319B-SU2C-06115118	PROS12319B-SU2C-06115118-Tumor-SM-4W2ND	
Biologically Relevant				Copy Number	RAD51B	Deletion				0.0	0.0																					0				RAD51B Deletion		PROS12319B-SU2C-06115118	PROS12319B-SU2C-06115118-Tumor-SM-4W2ND	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		PROS12319B-SU2C-06115118		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.543																									0				COSMIC Signature (version 2) 1 (54%)		PROS12319B-SU2C-06115118		
